

EBMT Transplantation and Cellular Therapy in Myeloid Malignancies Meeting

Paris, France | 21-22 January 2027



Acute
Leukaemia
ALWP



Chronic
Malignancies
CMWP

Thursday, 21 January 2027

09:00 – 13:00 Scientific Business Meetings

14:00 – 16:00 Session I: Novel insights on allo-HCT indications and management

Chairs: *Giorgia Battipaglia (IT) & Joanna Drozd-Sokołowska (PL)*

14:00 – 14:15 Welcome and Introduction

14:15 – 14:35 Allo-HCT Recommendation in Non-Classical MPN and MDS/MPN

14:35 – 14:55 Defining Remission and Relapse in MDS/MPN Overlaps

14:55 – 15:15 Update on Allo-HCT Indications in AML

15:15 – 15:35 Update on Allo-HCT for ALL in CR1

15:35 – 15:45 Case presentation Slot 1

15:45 – 15:55 Case presentation Slot 2

15:55 – 16:00 Discussion

Marie Robin (FR)

Eolia Brissot (FR)

Donal McLornan (UK)

Jordi Esteve (ES)

Sebastian Giebel (PL)

To be announced

To be announced

16:00 – 16:30 Coffee Break

16:30 – 17:15 Industry Symposium Slot

17:15 – 18:45 Session II: Session II: Allo-HCT in high-risk AML or MDS

Chairs: *Kavita Raj (UK) & Fabio Ciceri (IT)*

17:15 – 17:35 Role of Allo-HCT in High-Risk AML

17:35 – 17:55 Upfront versus Cyto-reduction before Transplant in MDS

17:55 – 18:15 Maintenance Post Allo in AML

18:15 – 18:25 Case presentation Slot 3

18:25 – 18:35 Case presentation Slot 4

18:35 – 18:45 Discussion

Annalisa Ruggeri (IT)

Marie Robin (FR)

Jaime Sanz (ES)

To be announced

To be announced

EBMT Transplantation and Cellular Therapy in Myeloid Malignancies Meeting

Paris, France | 21-22 January 2027



Acute
Leukaemia
ALWP



Chronic
Malignancies
CMWP

Friday, 22 January 2027

09:00 – 10:30

Session III: CAR-T Cell Therapy for ALL and AML/MDS: Where Do We Stand?

Chairs: Arnon Nagler (IL) & Guillermo Orti (ES)

09:00 – 09:20

Up to Date on CAR-T Therapy for AML and High-Risk MDS

09:20 – 09:40

Calreticulin-Targeted CAR T-cell Therapy in MPN

09:40 – 10:00

Update CAR-T in ALL

10:00 – 10:10

Case presentation Slot 5

10:10 – 10:20

Case presentation Slot 6

10:20 – 10:30

Discussion

Joanna Drozd-Sokołowska (PL)

Alex Rampotas (UK)

Eolia Brissot (FR)

To be announced

To be announced

10:30 – 11:30

Keynote Lecture

Chair: Marie Robin (FR)

10:30 – 11:15

Innovative therapies in myelofibrosis

11:15 – 11:30

Q&A

Jean-Jacques Kiladjian (FR)

11:30 – 12:00

Coffee Break

12:00 – 12:45

Industry Symposium Slot

12:45 – 14:15

Session IV: Post Allo-HCT Management in BCR::ABL1 mutated leukaemias

Chairs: Gesine Bug (DE) & Yves Chalandon (CH)

12:45 – 13:10

EBMT-Lead Expert Recommendation on CML Management Post Allo-HCT

13:10 – 13:35

Optimizing Management of Ph+ ALL after Transplant and CAR-T Cells

13:35 – 13:45

Case presentation Slot 7

13:45 – 13:55

Case presentation Slot 8

13:55 – 14:15

Discussion

Hugues de Lavallade (UK)

Gesine Bug (DE)

To be announced

To be announced

14:15 – 14:45

Coffee Break

14:45 – 16:50

Session V: Controversies

Chairs: Iman Abou Dalle (LB)

14:45 – 15:40

Is It Time for PTCy to Replace ATG as the Standard GVHD Prophylaxis in Myeloid Malignancies?

14:45 – 14:55

Case presentation Slot 9

To be announced

14:55 – 15:15

Yes

Patricia Chiusolo (IT)

15:15 – 15:35

No

Giorgia Battipaglia (IT)

15:35 – 15:40

Q&A

All

15:45 – 16:40

Second Transplantation or DLI in Patients with MDS or AML Relapsing after Transplantation?

15:45 – 15:55

Case presentation Slot 10

To be announced

15:55 – 16:15

Second allo

Giuliano Filippini (DE)

16:15 – 16:35

DLI

Christoph Schmid (DE)

16:35 – 16:40

Q&A

All

16:40 – 16:50

Take Home Messages & Closing Remarks

Marie Robin (FR)

Eolia Brissot (FR)

For further information, please get in contact with education.events@ebmt.org